Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Background: Vaginitis require complementary methods for adequate diagnosis. New technologies have been developed and need to be compared with those already established. Aims: The objective of this study was to compare the results of BD Affirm VPIII with Gram smear and liquid-based cytology in diagnosis of bacterial vaginosis (BV), Candida sp, and Trichomonas vaginalis. Materials and Methods: A cross-sectional study was performed in 90 women from March to November 2016 in a gynecology clinic in a Brazilian city, Fortaleza. The Affirm test, Gram, and Surepath were performed in vaginal samples. Categorical data was evaluated for sensibility, specificity, and predictive values. To quantify the agreement, the Kappa index was utilized. Results: Comparing Affirm test with Gram stain for BV and Surepath, the sensitivity was 83.3% and 27.8%, and the specificity was 62.2% and 95.5%, respectively. The Kappa index was 0.204 to Gram and 0.247 to Surepath. For Candida sp comparing with Gram and Surepath, the sensitivity was 61.1% and 56.3%, and the specificity was 93.3% and 100%, respectively. The Kappa index was 0.585 to Gram and 0.677 to Surepahth. Conclusion: The Affirm test had a fair concordance with Gram and Surepath in the diagnosis of BV, and substantial agreement in the diagnosis of Candida.